Abstract
No public abstract is available from the verified source records.
Open public full textRights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Charles Pei, Zeinab El Boghdadly, Lisa Blackburn, Naresh Bumma, Abdullah M. Khan, Srinivas Devarakonda, Elvira Umyarova, Don Benson, Ashley Rosko, Francesca Cottini
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Teclistamab in relapsed or refractory multiple myeloma
10.1056/nejmoa2203478 · 2022
Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma
10.1182/bloodadvances.2024013461 · 2024
Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience
10.1016/j.jtct.2023.12.016 · 2024
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study
10.1016/j.cmi.2024.02.023 · 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
10.1038/s41408-024-01003-z · 2024
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study
10.1002/cncr.35107 · 2024
High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network
10.1111/tid.12162 · 2014
Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation
10.1016/j.jcv.2017.08.006 · 2017
Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
10.1093/cid/ciad708 · 2024
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
10.1182/bloodadvances.2022009435 · 2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
10.1038/s41408-023-00879-7 · 2023
Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum
10.1093/cid/ciae321 · 2024
Risk of infections in multiple myeloma patients treated with bispecific antibodies
10.1182/blood-2024-206155 · 2024
Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation
10.1093/ofid/ofy230 · 2018
T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma
10.1158/1078-0432.ccr-23-3333 · 2024
No additional external references are available.